Press release
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting and Scientific Sessions taking place April 27 through April 30, 2025 in Boston.\n\n“The additional data across our portfolio presented at this year’s meeting highlight our commitment to furthering the science and standards of care in pulmonary hypertension and progressing the future of xenotransplantation,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “We look forward to a collaborative exchange with fellow researchers, clinicians, and thought leaders to collectively advance our understanding and push the boundaries of medical innovation.”\n\nPosters and presentations include:\n\nOral Session 05 – Donor Lung Engineering: Recent Developments and Continued Challenges, Sunday, April 27, 3:36 – 3:44 p.m. ET: 28 – Selectin and Integrin Blockade in Multi-Gene-Edited Pig Lungs Perfused with Human Blood. Presented by Zahra Habibabady, Massachusetts General Hospital.\n\nOral Session 05 – Donor Lung Engineering: Recent Developments and Continued Challenges, Sunday, April 27, 3:48 – 3:56 p.m. ET: 29 – Outcomes in 10GE Pig-to-Baboon Xenogeneic Lung Transplantation. Presented by Sho Takemoto, Massachusetts General Hospital.\n\nPoster Session 1. Pharmacy, Sunday, April 27, 6:00 – 7:00 p.m. ET: 803 – Developing Models for New Drugs in PAH: A Pharmacokinetic Simulation of Ralinepag. Presented by Andrew Stine, United Therapeutics.\n\nPoster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 447 – Clinical Correlations with Cardiac Power Output-to-Mass and Left Ventricular Global Longitudinal Strain in the Second Genetically Modified Porcine to Human Cardiac Xenotransplantation. Presented by Sarah Leventhal, University of Maryland.\n\nPoster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 448 – Clinical Correlations with Cardiac Power Output and Left Ventricular Global Longitudinal Strain in the Second Genetically Modified Porcine to Human Cardiac Xenotransplantation. Presented by Sarah Leventhal, University of Maryland.\n\nO...